PGAM1
Phosphoglycerate mutase 1
Also known as: PGAM-B, PGAM1_HUMAN, PGAMA
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P18669
- Gene
- PGAM1
- Ensembl
- ENSG00000171314
- Chromosome
- 10
- Canonical length
- 254 aa
- Protein class
- Candidate cardiovascular disease genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Mid piece
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a mutase that catalyzes the reversible reaction of 3-phosphoglycerate (3-PGA) to 2-phosphoglycerate (2-PGA) in the glycolytic pathway. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]
Canonical amino-acid sequenceUniProt
254 residues, UniProt reviewed canonical sequence.
>P18669|PGAM1
1 MAAYKLVLIR HGESAWNLEN RFSGWYDADL SPAGHEEAKR GGQALRDAGY EFDICFTSVQ
61 KRAIRTLWTV LDAIDQMWLP VVRTWRLNER HYGGLTGLNK AETAAKHGEA QVKIWRRSYD
121 VPPPPMEPDH PFYSNISKDR RYADLTEDQL PSCESLKDTI ARALPFWNEE IVPQIKEGKR
181 VLIAAHGNSL RGIVKHLEGL SEEAIMELNL PTGIPIVYEL DKNLKPIKPM QFLGDEETVR
241 KAMEAVAAQG KAKKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PGAM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 430 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 430 nTPM
- choroid plexus: 407 nTPM
- retina: 390 nTPM
- cerebral cortex: 357 nTPM
- adrenal gland: 283 nTPM
- midbrain: 281 nTPM
Single-cell type
- esophageal apical cells: 176 nCPM
- suprabasal keratinocytes: 127 nCPM
- esophageal suprabasal cells: 120 nCPM
- extravillous trophoblasts: 118 nCPM
- parietal cells: 117 nCPM
- migrating cytotrophoblasts: 114 nCPM
Immune cell
- total PBMC: 580 nTPM
- eosinophil: 574 nTPM
- classical monocyte: 434 nTPM
- non-classical monocyte: 424 nTPM
- intermediate monocyte: 367 nTPM
- neutrophil: 314 nTPM
Brain region
- pons: 363 nTPM
- thalamus: 361 nTPM
- choroid plexus: 347 nTPM
- hypothalamus: 326 nTPM
- cerebral cortex: 315 nTPM
- hippocampal formation: 303 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PGAM1.
Disease | ImmuneIEDB
Conditions an epitope on PGAM1 was assayed in.
- multiple sclerosis B cell
- allergic disease T cell
ReferencesPubMed · IEDB
Publications for PGAM1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases.
2010 · J Neuroimmunol · RCR 0.6 · 22 citations - Identification of antibodies as biological markers in serum from multiple sclerosis patients by immunoproteomic approach.
2011 · J Neuroimmunol · RCR 0.4 · 12 citations
Reference: B cellIEDB
1 publication
- High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.
2016 · Mol Cell Proteomics · RCR 2.5 · 66 citations
Reference: T cellIEDB
1 publication
- Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma.
2018 · Front Immunol · RCR 1.1 · 25 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.68
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.31
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- bisphosphoglycerate mutase activity
- hydrolase activity
- phosphoglycerate mutase activity
- protein kinase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PGAM1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PGAM1 as an antibody target. Whether an autoantibody or antibody against PGAM1 could matter depends on whether native PGAM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PGAM1 is annotated as secreted, so native PGAM1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PGAM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...